Diligence memo · auto-generated · as of July 2, 2026
Neopenda, PBC
Neopenda, PBC looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Neopenda, PBC operates in Biotechnology, based in CHICAGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Neopenda, PBC has raised $1.7M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $700K on 2022-08-18.
Most recent recorded round closed around 2024-11-15.
Valuation (modeled)modeled
Provath models Neopenda, PBC at approximately $732K (range $107K–$2.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.23× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 20 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 2.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 25% of Biotechnology peers (4293 compared).
Modeled value ranks above 2% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.